Self-activated arsenic manganite nanohybrids for visible and synergistic thermo/immuno-arsenotherapy.
Autor: | Zhai Y; Jiangsu Key Laboratory of Neuropsychiatric Diseases, College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China., Liu M; Jiangsu Key Laboratory of Neuropsychiatric Diseases, College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China., Yang T; Jiangsu Key Laboratory of Neuropsychiatric Diseases, College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China., Luo J; Jiangsu Key Laboratory of Neuropsychiatric Diseases, College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China., Wei C; Department of Radiology, Second Affiliated Hospital of Soochow University, Suzhou 215004, China. Electronic address: 20214133003@stu.suda.edu.cn., Shen J; Department of Radiology, Second Affiliated Hospital of Soochow University, Suzhou 215004, China. Electronic address: shenjunkang@suda.edu.cn., Song X; Jiangsu Key Laboratory of Neuropsychiatric Diseases, College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China., Ke H; Jiangsu Key Laboratory of Neuropsychiatric Diseases, College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China., Sun P; Department of Otolaryngology, the First Affiliated Hospital of Soochow University, Suzhou 215006, China., Guo M; Research Division of Clinical Pharmacology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China., Deng Y; Jiangsu Key Laboratory of Neuropsychiatric Diseases, College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China. Electronic address: ybyi@suda.edu.cn., Chen H; Jiangsu Key Laboratory of Neuropsychiatric Diseases, College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China; State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou 215123, China. Electronic address: chenhb@suda.edu.cn. |
---|---|
Jazyk: | angličtina |
Zdroj: | Journal of controlled release : official journal of the Controlled Release Society [J Control Release] 2022 Oct; Vol. 350, pp. 761-776. Date of Electronic Publication: 2022 Sep 08. |
DOI: | 10.1016/j.jconrel.2022.08.054 |
Abstrakt: | Arsenotherapy has been clinically exploited to treat a few types of solid tumors despite of acute promyelocytic leukemia using arsenic trioxide (ATO), however, its efficacy is hampered by inadequate delivery of ATO into solid tumors owing to the absence of efficient and biodegradable vehicles. Precise spatiotemporal control of subcellular ATO delivery for potent arsenotherapy thus remains challengeable. Herein, we report the self-activated arsenic manganite nanohybrids for high-contrast magnetic resonance imaging (MRI) and arsenotherapeutic synergy on triple-negative breast cancer (TNBC). The nanohybrids, composed of arsenic‑manganese-co-biomineralized nanoparticles inside albumin nanocages (As/Mn-NHs), switch signal-silent background to high proton relaxivity, and simultaneously afford remarkable subcellular ATO level in acidic and glutathione environments, together with reduced ATO resistance against tumor cells. Then, the nanohybrids enable in vivo high-contrast T (Copyright © 2022. Published by Elsevier B.V.) |
Databáze: | MEDLINE |
Externí odkaz: |